Senti Biosciences (SNTI) Proxy filing summary

Executive summary

• Amended Securities Purchase Agreement allows for additional tranches and new buyers, including a $2 million note purchase by NSG BioInnovation Fund, L.P., with closing expected within three business days of the amendment date.

• The amendment satisfies prior funding obligations under a merger agreement involving Celadon Partners SPV 35 Limited and provides for contingent value rights up to $60 million based on regulatory and sales milestones.

• The company received Nasdaq notices for non-compliance with minimum bid price and stockholders' equity requirements, but trading continues under the current symbol.

Voting matters and shareholder proposals

• A preliminary proxy statement includes a proposal for a reverse stock split to regain Nasdaq compliance, subject to board and shareholder approval.

• Proxy materials regarding the merger and contingent value rights will be mailed to shareholders after SEC filing of the definitive proxy statement.

Board of directors and corporate governance

• Directors and executive officers may participate in proxy solicitation related to the merger and contingent value rights transaction.